Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
NCT06211153 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31
Last updated 2024-01-18
Summary
This non-interventional study (NIS) was a retrospective chart review analyzing existing data from patients participating in the asciminib MAP.
Conditions
- Chronic Myeloid Leukemia With T315I Mutation
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-31
- Primary Completion
- 2022-12-15
- Completion
- 2022-12-15
Countries
- Switzerland
Study Locations
More Related Trials
-
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
NCT05611216 ·Status: COMPLETED
-
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
NCT00497991 ·Status: COMPLETED ·Phase: PHASE1
-
Asciminib RMP Study
NCT05943522 ·Status: RECRUITING
-
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
NCT06629584 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
NCT07150793 ·Status: COMPLETED
-
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
NCT06368414 ·Status: RECRUITING ·Phase: PHASE2
-
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
NCT05619978 ·Status: COMPLETED
-
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
NCT00451035 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591 ·Status: RECRUITING ·Phase: PHASE1
-
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
NCT02551718 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
NCT06427811 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
NCT03578367 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
NCT01051063 ·Status: COMPLETED ·Phase: PHASE1
-
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
NCT06092879 ·Status: ACTIVE_NOT_RECRUITING
-
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
NCT04150471 ·Status: UNKNOWN
-
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
NCT01593254 ·Status: COMPLETED ·Phase: PHASE2
-
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
NCT00098826 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042016 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
NCT00920140 ·Status: COMPLETED ·Phase: PHASE2
-
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05441514 ·Status: COMPLETED ·Phase: PHASE1
-
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2